Therapeutically relevant engraftment of a CRISPR-Cas9–edited HSC-enriched population with HbF reactivation in nonhuman primatesOlivier Humbert, Hans‐Peter Kiem, Jennifer E. Adair et al.|Science Translational Medicine|2019Cited by 113
Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineeringKathryn Michels, Shon Green, Alyssa Sheih et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 108
Vivovec™ Surface-Engineered Lentiviral Particles Mediate In Vivo CAR T Generation with Potent and Highly Durable Activity in Non-Human Primates and Tumor-Bearing Humanized MiceMaura H. Parker, Byoung Y. Ryu, Justin Theophilus Ulrich-Lewis et al.|Blood|2023Cited by 7
Nonclinical Toxicology, Biodistribution, and Pharmacokinetics of UB-VV111, an <i>In Vivo</i> Anti-CD19 CAR T Cell TherapyAlissa Brandes, Ryan Larson, A. Koo et al.|Blood|2024Cited by 5
438 In vivo Engineered CAR-T cells for oncology using a surface-engineered lentivirus platform: nonclinical safety and biodistributionAlissa Brandes, Ryan Larson, Soo Min Koo et al.|Regular and Young Investigator Award Abstracts|2023Cited by 1